C
C. Kent Osborne
Researcher at Baylor College of Medicine
Publications - 259
Citations - 43071
C. Kent Osborne is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 93, co-authored 232 publications receiving 39349 citations. Previous affiliations of C. Kent Osborne include University of Texas Health Science Center at San Antonio & Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond,Daniel F. Hayes,Mitch Dowsett,D. Craig Allred,Karen L. Hagerty,Sunil V. Badve,Patrick L. Fitzgibbons,Glenn Francis,Neil S. Goldstein,Malcolm Hayes,David G. Hicks,Susan C. Lester,Richard Love,Pamela B. Mangu,Lisa M. McShane,Keith Miller,C. Kent Osborne,Soonmyung Paik,Jane Perlmutter,Anthony Rhodes,Hironobu Sasano,Jared N. Schwartz,Fred C.G.J. Sweep,Sheila E. Taube,Emina Torlakovic,Paul N. Valenstein,Giuseppe Viale,Daniel W. Visscher,Thomas M. Wheeler,R. Bruce Williams,James L. Wittliff,Antonio C. Wolff +31 more
TL;DR: An international Expert Panel that conducted a systematic review and evaluation of the literature and developed recommendations for optimal IHC ER/PgR testing performance recommended that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences.
Journal ArticleDOI
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch,E P Winer,A S Coates,R. D. Gelber,M Piccart-Gebhart,B. Thürlimann,H.-J. Senn,Kathy S. Albain,Fabrice Andre,Jonas Bergh,Hervé Bonnefoi,Denisse Bretel-Morales,Harold J. Burstein,Fatima Cardoso,M. Castiglione-Gertsch,Alan S. Coates,Marco Colleoni,Alberto Costa,Giuseppe Curigliano,Nancy E. Davidson,Angelo Di Leo,Bent Ejlertsen,John F. Forbes,Richard D. Gelber,Michael Gnant,Aron Goldhirsch,Pamela J. Goodwin,Paul E. Goss,Jay R. Harris,Daniel F. Hayes,Clifford A. Hudis,James N. Ingle,Jacek Jassem,Zefei Jiang,Per Karlsson,Sibylle Loibl,Monica Morrow,Moïse Namer,C. Kent Osborne,Ann H. Partridge,Frédérique Penault-Llorca,Charles M. Perou,Martine Piccart-Gebhart,Kathleen I. Pritchard,Emiel J. Th. Rutgers,Felix Sedlmayer,Vladimir Semiglazov,Z Shao,Ian E. Smith,Beat Thürlimann,Masakazu Toi,Andrew Tutt,Michael Untch,Giuseppe Viale,Toru Watanabe,Nicholas Wilcken,Eric P. Winer,William C. Wood +57 more
TL;DR: The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy.
Journal ArticleDOI
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
TL;DR: IHC is superior to the LBA for assessing ER status in primary breast cancer because it is easier, safer, and less expensive, and has an equivalent or better ability to predict response to adjuvant endocrine therapy.
Journal ArticleDOI
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Xiaoxian Li,Michael T. Lewis,Jian Huang,Carolina Gutierrez,C. Kent Osborne,Meng Fen Wu,Susan G. Hilsenbeck,Anne Pavlick,Xiaomei Zhang,Gary C. Chamness,Helen Wong,Jeffrey M. Rosen,Jenny C. Chang +12 more
TL;DR: These studies provide clinical evidence for a subpopulation of chemotherapy-resistant breast cancer-initiating cells and, in combination with conventional therapy, specific pathway inhibitors may provide a therapeutic strategy for eliminating these cells to decrease recurrence and improve long-term survival.
Journal ArticleDOI
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain,William E. Barlow,Steven Shak,Gabriel N. Hortobagyi,Robert B. Livingston,I-Tien Yeh,Peter M. Ravdin,Roberto Bugarini,Frederick L. Baehner,Nancy E. Davidson,George W. Sledge,Eric P. Winer,Clifford A. Hudis,James N. Ingle,Edith A. Perez,Kathleen I. Pritchard,Lois E. Shepherd,Julie Gralow,Carl Yoshizawa,D. Craig Allred,C. Kent Osborne,Daniel F. Hayes +21 more
TL;DR: The recurrence score is prognostic for tamoxifen-treated patients with positive nodes and predicts significant benefit of CAF in tumours with a high recurrence scores, as well as overall survival and breast-cancer-specific survival.